1127 Biogen Sage
BioCentury & Getty Images


With $1.5B Sage deal, Biogen bolsters Phase III pipeline ahead of aducanumab decision

Nov 27, 2020 | 5:09 PM GMT

Biogen is paying Sage $1.5 billion up front to gain rights to two late-stage CNS products, bolstering the company’s pipeline as it approaches one of the biggest binary decisions in recent industry memory

Read the full 585 word article

How to gain access

Continue reading with a
two-week free trial.